NCT07495852 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
| NCT ID | NCT07495852 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Glaukos Corporation |
| Condition | Glaucoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 510 participants |
| Start Date | 2026-02-17 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 510 participants in total. It began in 2026-02-17 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07495852 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07495852 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 510 participants.
Is NCT07495852 currently recruiting?
Yes, NCT07495852 is actively recruiting participants. Contact the research team at ClinicalResearch@glaukos.com for enrollment information.
Where is the NCT07495852 trial being conducted?
This trial is being conducted at Dothan, United States.
Who is sponsoring the NCT07495852 clinical trial?
NCT07495852 is sponsored by Glaukos Corporation. The trial plans to enroll 510 participants.